Zwanziger on Alere’s NGAL test

By On 9. February 2012 · Leave a Comment · In BioPorto

Important highlight from Alere’s Q4 earnings session:

“Additionally, in January we launched our Cardiorenal panel in Europe, for use on the Triage platform. The Cardiorenal panel is the world’s first point of care test to combine BNP and NGAL to aid in the real-time assessment of cardiac and renal status. We believe this panel will continue to support greater adoption of NGAL as a novel biomarker for the evaluation of kidney function.”

About Stengaard

BioPorto investor from way back when... I've invested in BioPorto ever since they made their debut on the danish stock exchange, it been a looooong journey with many obstacles. But well worth it all if Bioporto maintains their patent after the proceedings in 2014, and enters into agreements with Global Distributors in 2012 and 2013 If not, then it'll take another xx.years 🙂

Related posts:

  1. Just in case your German is less than perfect Neue biomarker verbessern voraussage akuten. in short : NGAL is...
  2. NGAL Data Summary / Metaanalysis NGAL Clinical Communication Platform Besides the cut-offs, which certainly appears in...
  3. Is Bioporto “fencing in” the ER’s? Is BioPorto trying to prevent usage of Alere’s Triage NGAL-test  in...
  4. Will they ever bring the NGAL test to the market? In November 2010, a productmanager from Beckman Coulter Diagnostics said:...
  5. An amazing survey – it’s a MUST read :) http://www.urologytoday.net/article/new-biomarker-improves-acute-kidney-injury-diagnosis/ quotes: This study describes a new biomarker (NGAL) that...
Tagged with: • •
 

Leave a Reply

Your email address will not be published. Required fields are marked *

Set your Twitter account name in your settings to use the TwitterBar Section.